Teduglutide
Who holds supplier records for Teduglutide? 5 organisations hold a current record for Teduglutide: an active US FDA Type II Drug Master File. Recorded organisation countries for current records: India (2), United States (1) and Italy (1); not recorded for 1.
Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records
Cite as: PharmaTek, “Teduglutide: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/teduglutide
Reading the evidence
- 5 current records
Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.
- 2 with a company-level GMP certificate on record
These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.
- US product patents listed
The latest patent listed in the FDA Orange Book for an approved product containing Teduglutide expires 1 May 2026. Product, formulation and method-of-use patents do not by themselves stop the ingredient being supplied or other products being approved.
Current records (5)
Organisations holding an active US FDA Type II Drug Master File or a CEP for Teduglutide. Country is the organisation's recorded country, not necessarily the manufacturing site.
- ALP PHARM BEIJING CO LTDActive DMF 35438 · latest filing Dec 2020
- AMBIO INCUnited StatesActive DMF 30583 · latest filing Aug 2016
- Biocon LimitedIndiaActive DMF 43910 · latest filing Mar 2026
- MSN LIFE SCIENCES PRIVATE LIMITEDIndia Company GMP cert on recordActive DMF 37596 · latest filing Dec 2022
- OLON SPAItaly Company GMP cert on recordActive DMF 43291 · latest filing Jan 2026
The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.
US product patents and exclusivity
The FDA Orange Book lists patents and exclusivities for specific approved products (1 listed product contain Teduglutide). The latest listed patent expires 1 May 2026. The latest listed exclusivity ended 16 May 2026. These dates are product-specific: they can cover a formulation, a combination or a method of use, and do not on their own show whether the ingredient is protected or whether generics are already approved. Check the individual product entries before planning a launch.
Overview
Teduglutide is a recombinant form of human glucagon-like peptide-2 (GLP-2) that enhances intestinal absorption and is used to treat adults with short bowel syndrome who are dependent upon parenteral support. It increases intestinal and portal blood flow and inhibits gastric acid secretion.
Therapeutic areas
Record history
No change to the current records between 13 Nov 2026 and 16 Nov 2026.
Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week
What these records establish
- An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
- A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
- Historical records show a past filing, not current supply.
- Company GMP certificates are matched to the organisation, not to the site making this substance.
- A substance missing from these registers is not evidence that no supplier exists.
Frequently asked questions
Which organisations hold current supplier records for Teduglutide?
5 organisations hold an active US FDA Type II Drug Master File or a CEP for Teduglutide: ALP PHARM BEIJING CO LTD, AMBIO INC (United States), Biocon Limited (India), MSN LIFE SCIENCES PRIVATE LIMITED (India) and OLON SPA (Italy). A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.
Which Teduglutide Drug Master Files are active?
ALP PHARM BEIJING CO LTD (DMF 35438), AMBIO INC (DMF 30583), Biocon Limited (DMF 43910), MSN LIFE SCIENCES PRIVATE LIMITED (DMF 37596) and OLON SPA (DMF 43291). The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.
Does the FDA Orange Book list patents for products containing Teduglutide?
Yes. The latest patent listed for an approved US product containing Teduglutide expires 1 May 2026, across 1 listed products. These patents protect specific products, formulations or uses. They do not by themselves mean the ingredient is protected, and generic versions of other products may already be approved.
How do I qualify a Teduglutide supplier?
Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.
Do you supply Teduglutide?
Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.